NCT00040105View on ClinicalTrials.gov

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Leukemia, Myeloid, Chronic
Interventions
DRUG

Zarnestra (R115777)

"Starting Dose:~300 mg by mouth (PO) Twice daily"

DRUG

Gleevec (Imatinib mesylate)

"Starting Dose:~300 mg By Mouth (PO) daily"

Trial Locations (1)

77030

M.D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00040105 - Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter